What is the biggest challenge your company has faced moving from preclinical to first-in-human trials?
*
Regulatory strategy & IND prep
Trial design & dose selection
Biomarker strategy
Staffing/expertise gaps
Funding constraints
Site activation/enrollment delays
Other
Which of the following roles are you most likely to outsource during early development?
*
Regulatory affairs
Project management
Clinical operations (e.g., CRA, CTA)
Biostatistics & data management
Medical writing
None – we plan to build in-house capacity
What’s your expected timeline from IND submission to first patient in (FPI)?
*
<3 months
3–6 months
6–9 months
9 months
Not sure yet
How would you describe your current resourcing model for early development?
*
Mostly internal team
Primarily functional outsourcing (FSP)
Full-service CRO
Hybrid approach
Not yet defined
Would you be interested in learning more about flexible, global resourcing models tailored to biotech needs?
*
Yes, please contact me
No thanks
Name
First Name
Last Name
Company
Email
example@example.com
Country/Region
Please Select
North America
Latin America
Asia Pacific
Middle East
Northern Europe
Eastern Europe
Southern Europe
Western Europe
DACH
Africa
Commonwealth of Independent States
Other
Area of Interest
Please Select
Dermatology, Immunology & Inflammatory Disease
Internal Medicine
Neuroscience
Oncology & Hematology
Ophthalmology
Rare Diseases/Orphan Drugs
Strategic Resourcing
Functional Service Partnerships (FSP)
Other
Submit
Should be Empty: